232 related articles for article (PubMed ID: 36587744)
21. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
22. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
Front Immunol; 2022; 13():873789. PubMed ID: 35572515
[TBL] [Abstract][Full Text] [Related]
23. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Iovino L; Wu QV; Voutsinas J; Panaite L; Mullane E; Lynch RC; Ujjani C; Smith SD; Gopal AK; Till BG; Milano F; Chow V; Gauthier J; Turtle CJ; Maloney DG; Shadman M
J Cell Mol Med; 2022 Dec; 26(24):5976-5983. PubMed ID: 36453136
[TBL] [Abstract][Full Text] [Related]
24. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
25. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
Ababneh HS; Ng AK; Frigault MJ; Abramson JS; Johnson PC; Jacobson CA; Patel CG
Haematologica; 2023 Nov; 108(11):2972-2981. PubMed ID: 37317884
[TBL] [Abstract][Full Text] [Related]
26. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract][Full Text] [Related]
27. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Yamauchi N; Maruyama D
Eur J Haematol; 2024 May; 112(5):662-677. PubMed ID: 38168033
[TBL] [Abstract][Full Text] [Related]
28. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
29. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
[TBL] [Abstract][Full Text] [Related]
30. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Breen WG; Hathcock MA; Young JR; Kowalchuk RO; Bansal R; Khurana A; Bennani NN; Paludo J; Villasboas Bisneto JC; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
J Hematol Oncol; 2022 Mar; 15(1):36. PubMed ID: 35346315
[TBL] [Abstract][Full Text] [Related]
31. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
Yu L; Zou R; He J; Qu C
Crit Rev Oncol Hematol; 2024 Jul; 199():104390. PubMed ID: 38782146
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
33. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
Saifi O; Breen WG; Lester SC; Rule WG; Stish BJ; Rosenthal A; Munoz J; Lin Y; Bansal R; Hathcock MA; Bennani NN; Paludo J; Khurana A; Villasboas JC; Johnston PB; Ansell SM; Iqbal M; Moustafa MA; Murthy HS; Kharfan-Dabaja MA; Hoppe BS; Peterson JL
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):999-1007. PubMed ID: 36563910
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
35. Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy.
Zhou L; Li P; Ye S; Tang X; Wang J; Liu J; Liang A
Front Med; 2020 Dec; 14(6):786-791. PubMed ID: 32789732
[TBL] [Abstract][Full Text] [Related]
36. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
38. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
39. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
40. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
